Pillar Pacific Capital Management LLC Sells 1,445 Shares of Alexion Pharmaceuticals, Inc. (ALXN)

Pillar Pacific Capital Management LLC decreased its holdings in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 7.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 18,050 shares of the biopharmaceutical company’s stock after selling 1,445 shares during the quarter. Pillar Pacific Capital Management LLC’s holdings in Alexion Pharmaceuticals were worth $1,757,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in ALXN. Quantamental Technologies LLC acquired a new position in Alexion Pharmaceuticals in the fourth quarter valued at about $651,000. Hills Bank & Trust Co. lifted its position in shares of Alexion Pharmaceuticals by 5.6% during the fourth quarter. Hills Bank & Trust Co. now owns 8,175 shares of the biopharmaceutical company’s stock worth $796,000 after purchasing an additional 431 shares in the last quarter. Ingalls & Snyder LLC lifted its position in shares of Alexion Pharmaceuticals by 217.1% during the fourth quarter. Ingalls & Snyder LLC now owns 22,444 shares of the biopharmaceutical company’s stock worth $2,185,000 after purchasing an additional 15,367 shares in the last quarter. Calamos Wealth Management LLC acquired a new stake in shares of Alexion Pharmaceuticals during the fourth quarter worth about $2,208,000. Finally, We Are One Seven LLC acquired a new stake in shares of Alexion Pharmaceuticals during the fourth quarter worth about $79,000. 94.20% of the stock is owned by institutional investors and hedge funds.

In related news, EVP Indrani Lall Franchini sold 2,605 shares of the stock in a transaction on Wednesday, November 28th. The stock was sold at an average price of $118.13, for a total transaction of $307,728.65. Following the completion of the sale, the executive vice president now directly owns 29,304 shares of the company’s stock, valued at $3,461,681.52. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Ludwig Hantson sold 3,244 shares of the stock in a transaction on Monday, December 31st. The stock was sold at an average price of $95.85, for a total value of $310,937.40. Following the sale, the chief executive officer now directly owns 150,696 shares of the company’s stock, valued at $14,444,211.60. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 9,093 shares of company stock valued at $929,603. Corporate insiders own 4.35% of the company’s stock.

Shares of ALXN opened at $125.18 on Thursday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 2.48 and a current ratio of 2.88. The company has a market cap of $27.77 billion, a PE ratio of 17.66, a price-to-earnings-growth ratio of 0.89 and a beta of 1.56. Alexion Pharmaceuticals, Inc. has a 12-month low of $92.56 and a 12-month high of $140.77.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Monday, February 4th. The biopharmaceutical company reported $2.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.60 by $0.54. The business had revenue of $1.13 billion for the quarter, compared to analyst estimates of $1.06 billion. Alexion Pharmaceuticals had a net margin of 1.88% and a return on equity of 18.15%. The company’s revenue for the quarter was up 24.1% compared to the same quarter last year. During the same period last year, the firm posted $1.48 earnings per share. Analysts anticipate that Alexion Pharmaceuticals, Inc. will post 8.51 earnings per share for the current year.

ALXN has been the topic of a number of recent research reports. Leerink Swann set a $181.00 target price on shares of Alexion Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, October 24th. BidaskClub lowered shares of Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, December 18th. Credit Suisse Group set a $156.00 price target on shares of Alexion Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, November 13th. Oppenheimer set a $165.00 price target on shares of Alexion Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, November 26th. Finally, Zacks Investment Research lowered shares of Alexion Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 31st. Five analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $162.33.

WARNING: This piece was reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of US & international copyright legislation. The original version of this piece can be read at https://www.baseballdailydigest.com/news/2019/02/14/pillar-pacific-capital-management-llc-sells-1445-shares-of-alexion-pharmaceuticals-inc-alxn.html.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.

See Also: Why is cost of goods sold important?

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply